ANTI-SUMO-1 CLONE 4D12

General description

Small ubiquitin-related modifier 1 (UniProt P63165, P63166, Q5I0H3; also known as GAP-modifying protein 1, GMP1, Sentrin, SMT3 homolog 3, Ubiquitin-homology domain protein PIC1, Smt3C, SUMO-1, Ubiquitin-like protein SMT3C, Ubiquitin-like protein UBL1) is encoded by the human SUMO1 (also known as SMT3C, SMT3H3, UBL1,OK/SW-cl.43), mouse & rat Sumo1 (also known as Smt3c, Smt3h3, Ubl1) gene (Gene ID 7341, 22218, 301442, respectively). SUMOylation, protein posttranslation modification by small ubiquitin-like modifier (SUMO), is a signaling event in many cellular processes. SUMO proteins are translated as immature precursors and subsequently converted to their mature forms through the activity of sentrin/SUMO-specific proteases (SENPs). As is the case with ubiquitination, SUMOylation is a reversible process. SUMO E1 activating enzyme, E2 conjugating enzyme, and E3 ligase mediate SUMOylation of substrate proteins, while SENPs are responsible for the deSUMOylation. SUMOylation usually occurs at lysine residues in the consensus ΨKxD/E motif, although not all such lysines become SUMOylated and SUMOylation can also occur on lysine residues outside of this motif. SUMO2 and 3 share 97% identity at the amino acid level, while SUMO1 shares approximately 50% and SUMO4 shares about 87% identity with SUMO2/3. SUMO4 is the only SUMO member whose ctivation and conjugation has not been demonstrated. In addition to difference in their target substrates, SUMO2/3 can be SUMOylated and form chains, whereas SUMO1 cannot and may serve as chain terminator.

Specificity

Clone 4D12 detects SUMO-1 and SUMO-1-modified (SUMOylated) proteins.

SUMO-1 sequence is 100% conserved among canine, human, murine, and rat species. Predicted to react with a broad-range of mammalian species based on high sequence homology.

Immunogen

GST-tagged recombinant full-length human SUMO-1.

Application

Detect SUMO1 and SUMP1-modified (SUMOylated) proteins using this rat monoclonal Anti-SUMO-1, clone 4D12, Cat. No. MABS1223, validated for use in Immunocytochemistry and Western Blotting.

Immunocytochemistry Analysis: A representative lot detected SUMO-1 nuclear puncta enriched in heterochromatin and co-localized with SUMO-2/3 immunoreactivity by indirect fluorescence staining of 4% paraformaldehyde-fixed, 0.2% Triton X-100-permeabilized C-33A human cervical carcinoma cells (Uchimura, Y., et al. (2006). J. Biol. Chem. 281(32):23180-23190).

Western Blotting Analysis: A representative lot detected SUMO-1 and SUMO-1-modified (SUMOylated) proteins in human cervical carcinoma C-33A nuclear extract (Uchimura, Y., et al. (2006). J. Biol. Chem. 281(32):23180-23190).

Research Category
Signaling

Quality

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:250 dilution of this hybridoma culture supernatant detected SUMO-1-modified (SUMOylated) proteins in 10 µg of HeLa cell lysate.

Target description

Variable depending on the size(s) of the SUMOylated protein(s). 11.00 kDa (human/mouse/rat mature SUMO-1; a.a. 2-97) calculated. Uncharacterized bands may be observed in some lysate(s).

Physical form

Format: Unpurified

Rat monoclonal hybridoma culture supernatant with 0.05% sodium azide

Unpurified.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.